Focus is not about being fixed, but about achieving the ultimate in what one can do. After 20 years of deep cultivation in the field of regenerative medicine, Shandong Yantai Zhenghai Biotechnology Co., Ltd. has filled a technological gap in the field of regenerative medicine in China with its hard core strength, from the unparalleled development of oral repair membranes to the accumulation of active bone repair materials. At the beginning of its establishment, Zhenghai Biotech focused on oral products as its main research direction. In 2007, the first product developed by Zhenghai Biotech, the Haiao Oral Repair Film, obtained a domestic medical device registration certificate and was officially mass-produced and launched into the market. The main component of the repair membrane comes from the xenogeneic bovine acellular dermal matrix, which can promote tissue regeneration and wound repair, and is degraded and absorbed with the reconstruction of new tissues. It has advantages such as good tissue compatibility, no inflammatory reactions, and no immune rejection reactions. According to statistics, the domestic market share of Haiao oral repair film is about 10%, ranking among the top domestic oral repair film brands. 15m? Freeze dryer? Guangming Network reporter Liu Hanxu/Photography innovation exploration is endless. As a technology-based company, Zhenghai Biotech has embarked on the research and development of active biological bones on the basis of traditional biological active materials. Active biological bone refers to a new type of bone repair material formed by the combination of collagen containing bone scaffold materials and modified recombinant human bone morphogenetic proteins with collagen specific binding ability. By combining decellularization technology and genetic engineering technology, efficient therapeutic and prognostic effects can be achieved, "said Zhang Donggang, Deputy General Manager of the company. After more than ten years, Yantai Zhenghai Biotechnology Co., Ltd. has successfully achieved a new breakthrough in the research and development of bone repair materials. Last October, the independently developed Haiyu Active Biological Bone by Yantai Zhenghai Biotechnology Co., Ltd. successfully passed the review of the National Drug Administration and obtained the medical device registration certificate, becoming the only active biological bone product approved for marketing in China. Innovation cannot do without the support of tax and fee policies. The R&D investment cycle in the biopharmaceutical industry is long and large-scale, and most of the time is spent exploring. Policy support is crucial to continue the path of independent research and development, "the financial director of Zhenghai Biotechnology told reporters. Starting from 2021, Zhenghai Biotech has enjoyed a discount of over 10 million yuan in high-tech enterprise income tax for consecutive years, and an additional deduction of over 30 million yuan for research and development expenses. The research and development investment in the field of biomedicine varies day by day, and even more or less is different. With the support of such good policies, we are even more motivated to carry out scientific research and technological transformation, "said Zhao Li. The organizer provided pictures aimed at the forefront of regenerative medicine and opened up a new track. In 2019, Zhenghai Biotechnology Co., Ltd. was awarded the title of the first batch of specialized, refined, and innovative "Little Giant" enterprises in the country. The company has undertaken more than 80 national and provincial level scientific and technological development projects, obtained 67 authorized patents, including 40 authorized invention patents and 95 registered trademarks, covering multiple fields such as oral implantation, oral surgery, neurosurgery, orthopedics, medical aesthetics and plastic surgery. In the future, Zhenghai Biotech will continue to transform its technological achievements, accelerate the transformation of old and new driving forces, and continue to contribute to improving the quality of life of the people, enhancing the level of social medical health, and promoting the innovative development of the biopharmaceutical industry